MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 461205 | Name: Regadenoson hydrate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Regadenoson is an A2A adenosine receptor agonist that is a coronary vasodilator that is commonly used in pharmacologic stress testing.

Chemical Structure

Regadenoson hydrate
Regadenoson hydrate
CAS#875148-45-1 (hydrate)

Theoretical Analysis

MedKoo Cat#: 461205

Name: Regadenoson hydrate

CAS#: 875148-45-1 (hydrate)

Chemical Formula: C15H20N8O6

Exact Mass:

Molecular Weight: 408.37

Elemental Analysis: C, 44.12; H, 4.94; N, 27.44; O, 23.51

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
313348-27-5 (free) 875148-45-1 (hydrate)
Synonym
Regadenoson; Lexiscan; Regadenoson hydrate; CVT-3146; CVT 3146; CVT3146;
IUPAC/Chemical Name
1-(6-amino-9-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9H-purin-2-yl)-N-methyl-1H-pyrazole-4-carboxamide hydrate
InChi Key
CDQVVPUXSPZONN-WPPLYIOHSA-N
InChi Code
InChI=1S/C15H18N8O5.H2O/c1-17-13(27)6-2-19-23(3-6)15-20-11(16)8-12(21-15)22(5-18-8)14-10(26)9(25)7(4-24)28-14;/h2-3,5,7,9-10,14,24-26H,4H2,1H3,(H,17,27)(H2,16,20,21);1H2/t7-,9-,10-,14-;/m1./s1
SMILES Code
O=C(C1=CN(C2=NC(N)=C3N=CN([C@H]4[C@@H]([C@@H]([C@@H](CO)O4)O)O)C3=N2)N=C1)NC.[H]O[H]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 408.37 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Johnson NP, Gould KL. Regadenoson versus dipyridamole hyperemia for cardiac PET imaging. JACC Cardiovasc Imaging. 2015 Apr;8(4):438-447. doi: 10.1016/j.jcmg.2014.11.016. Epub 2015 Mar 18. PubMed PMID: 25797122. 2: Mahmarian JJ, Peterson LE, Xu J, Cerqueira MD, Iskandrian AE, Bateman TM, Thomas GS, Nabi F. Regadenoson provides perfusion results comparable to adenosine in heterogeneous patient populations: a quantitative analysis from the ADVANCE MPI trials. J Nucl Cardiol. 2015 Apr;22(2):248-61. doi: 10.1007/s12350-014-9981-6. Epub 2014 Oct 7. PubMed PMID: 25287737. 3: Brink HL, Dickerson JA, Stephens JA, Pickworth KK. Comparison of the Safety of Adenosine and Regadenoson in Patients Undergoing Outpatient Cardiac Stress Testing. Pharmacotherapy. 2015 Dec;35(12):1117-23. doi: 10.1002/phar.1669. PubMed PMID: 26684552. 4: Bitar A, Mastouri R, Kreutz RP. Caffeine Consumption and Heart Rate and Blood Pressure Response to Regadenoson. PLoS One. 2015 Jun 22;10(6):e0130487. doi: 10.1371/journal.pone.0130487. eCollection 2015. PubMed PMID: 26098883; PubMed Central PMCID: PMC4476756. 5: van Nunen LX, Lenders GD, Schampaert S, van 't Veer M, Wijnbergen I, Brueren GR, Tonino PA, Pijls NH. Single bolus intravenous regadenoson injection versus central venous infusion of adenosine for maximum coronary hyperaemia in fractional flow reserve measurement. EuroIntervention. 2015 Dec;11(8):905-13. doi: 10.4244/EIJY14M08_10. PubMed PMID: 25136887. 6: Cury RC, Kitt TM, Feaheny K, Blankstein R, Ghoshhajra BB, Budoff MJ, Leipsic J, Min JK, Akin J, George RT. A randomized, multicenter, multivendor study of myocardial perfusion imaging with regadenoson CT perfusion vs single photon emission CT. J Cardiovasc Comput Tomogr. 2015 Mar-Apr;9(2):103-12.e1-2. doi: 10.1016/j.jcct.2015.01.002. Epub 2015 Jan 7. PubMed PMID: 25726411. 7: Prasad A, Zareh M, Doherty R, Gopal A, Vora H, Somma K, Mehra A, Clavijo LC, Matthews RV, Shavelle DM. Use of regadenoson for measurement of fractional flow reserve. Catheter Cardiovasc Interv. 2014 Feb 15;83(3):369-74. doi: 10.1002/ccd.25055. Epub 2013 Jul 3. PubMed PMID: 23765847. 8: Cury RC, Kitt TM, Feaheny K, Akin J, George RT. Regadenoson-stress myocardial CT perfusion and single-photon emission CT: rationale, design, and acquisition methods of a prospective, multicenter, multivendor comparison. J Cardiovasc Comput Tomogr. 2014 Jan-Feb;8(1):2-12. doi: 10.1016/j.jcct.2013.09.004. Epub 2013 Oct 18. PubMed PMID: 24314823. 9: Saab R, Zouk AN, Mastouri R, Skaar TC, Philips S, Kreutz RP. AMPD1 polymorphism and response to regadenoson. Pharmacogenomics. 2015 Nov;16(16):1807-15. doi: 10.2217/pgs.15.116. Epub 2015 Nov 10. PubMed PMID: 26554440; PubMed Central PMCID: PMC4826562. 10: Rangel MO, Morales Demori R, Voll ST, Wassouf M, Dick R, Doukky R. Severe chronic kidney disease as a predictor of benefit from aminophylline administration in patients undergoing regadenoson stress myocardial perfusion imaging: A substudy of the ASSUAGE and ASSUAGE-CKD trials. J Nucl Cardiol. 2015 Oct;22(5):1008-18. doi: 10.1007/s12350-014-0036-9. Epub 2014 Dec 11. PubMed PMID: 25500799. 11: Farzaneh-Far A, Shaw LK, Dunning A, Oldan JD, O'Connor CM, Borges-Neto S. Comparison of the prognostic value of regadenoson and adenosine myocardial perfusion imaging. J Nucl Cardiol. 2015 Aug;22(4):600-7. doi: 10.1007/s12350-015-0155-y. Epub 2015 May 19. PubMed PMID: 25987234. 12: Ghimire G, Hage FG, Heo J, Iskandrian AE. Regadenoson: a focused update. J Nucl Cardiol. 2013 Apr;20(2):284-8. doi: 10.1007/s12350-012-9661-3. Review. PubMed PMID: 23229649. 13: Abdelmoneim SS, Mulvagh SL, Xie F, O'Leary E, Adolphson M, Omer MA, Nhola LF, Huang R, Warta SJ, Kirby B, Porter TR. Regadenoson Stress Real-Time Myocardial Perfusion Echocardiography for Detection of Coronary Artery Disease: Feasibility and Accuracy of Two Different Ultrasound Contrast Agents. J Am Soc Echocardiogr. 2015 Dec;28(12):1393-400. doi: 10.1016/j.echo.2015.08.011. Epub 2015 Sep 26. PubMed PMID: 26416199. 14: Jager PL, Buiting M, Mouden M, Oostdijk AH, Timmer J, Knollema S. [Regadenoson as a new stress agent in myocardial perfusion imaging. Initial experience in The Netherlands]. Rev Esp Med Nucl Imagen Mol. 2014 Nov-Dec;33(6):346-51. doi: 10.1016/j.remn.2014.04.004. Epub 2014 May 23. Spanish. PubMed PMID: 24862658. 15: Stolker JM, Lim MJ, Shavelle DM, Morris DL, Angiolillo DJ, Guzman LA, Kennedy KF, Weber E, Zareh M, Neumayr RH, Zenni MM. Pooled comparison of regadenoson versus adenosine for measuring fractional flow reserve and coronary flow in the catheterization laboratory. Cardiovasc Revasc Med. 2015 Jul-Aug;16(5):266-71. doi: 10.1016/j.carrev.2015.05.011. Epub 2015 Jun 5. PubMed PMID: 26242981. 16: Nguyen KL, Bandettini WP, Shanbhag S, Leung SW, Wilson JR, Arai AE. Safety and tolerability of regadenoson CMR. Eur Heart J Cardiovasc Imaging. 2014 Jul;15(7):753-60. doi: 10.1093/ehjci/jet278. Epub 2014 Jan 21. PubMed PMID: 24451179; PubMed Central PMCID: PMC4060784. 17: Jackson S, Anders NM, Mangraviti A, Wanjiku TM, Sankey EW, Liu A, Brem H, Tyler B, Rudek MA, Grossman SA. The effect of regadenoson-induced transient disruption of the blood-brain barrier on temozolomide delivery to normal rat brain. J Neurooncol. 2016 Feb;126(3):433-9. doi: 10.1007/s11060-015-1998-4. Epub 2015 Dec 1. PubMed PMID: 26626489; PubMed Central PMCID: PMC4733584. 18: Rosenblatt J, Mooney D, Dunn T, Cohen M. Asystole following regadenoson infusion in stable outpatients. J Nucl Cardiol. 2014 Oct;21(5):862-8. doi: 10.1007/s12350-014-9898-0. Epub 2014 May 31. PubMed PMID: 24879452. 19: Tejani FH, Thompson RC, Kristy R, Bukofzer S. Effect of caffeine on SPECT myocardial perfusion imaging during regadenoson pharmacologic stress: a prospective, randomized, multicenter study. Int J Cardiovasc Imaging. 2014 Jun;30(5):979-89. doi: 10.1007/s10554-014-0419-7. Epub 2014 Apr 17. PubMed PMID: 24737255; PubMed Central PMCID: PMC4008779. 20: Vasu S, Bandettini WP, Hsu LY, Kellman P, Leung S, Mancini C, Shanbhag SM, Wilson J, Booker OJ, Arai AE. Regadenoson and adenosine are equivalent vasodilators and are superior than dipyridamole- a study of first pass quantitative perfusion cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2013 Sep 24;15:85. doi: 10.1186/1532-429X-15-85. PubMed PMID: 24063278; PubMed Central PMCID: PMC3851492.